



As the U.S. Cancer Statistics public use databases contain data from both CDC's NPCR and NCI's SEER program, data-use agreements from both programs must be signed.

#### Steps for accessing the data—

1. NCI offers two data products: SEER Research and SEER Research Plus. You must have [SEER Research Plus](#) level access.  
  
This step is not complete until you have completed the user authentication process and received e-mail confirmation that your SEER\*Stat account was created or updated.
2. Complete and sign the U.S. Cancer Statistics Public Use Research Data Agreement on pages 2 and 3 below.
3. E-mail this form to [uscdata@imsweb.com](mailto:uscdata@imsweb.com). Your request for access will be processed within 2 business days and you will receive a response notifying you when you have access to the databases in the SEER\*Stat software.
4. Download and install NCI's [SEER\\*Stat software](#). The site also provides training tutorials.

New research data agreements are required for each data submission year. You will receive e-mail reminders to complete data agreements when new data become available.

**National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology, and End Results (SEER) Incidence—U.S. Cancer Statistics  
Public Use Research Databases Data Use Agreement  
2022 Data Submission**

The Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI) make NPCR and SEER data available to the public and researchers through various data release activities. The NPCR and SEER Incidence—U.S. Cancer Statistics Public Use Research Databases are an unrestricted subset of data submitted to CDC and NCI and made available only through the National Cancer Institute's SEER\*Stat statistical software.

CDC has obtained an assurance of confidentiality agreement for NPCR pursuant to Section 308(d) of the Public Health Service Act, 42 U.S.C. 242m(d). Any effort to determine the identity of any reported cases, or to use the information for any purpose other than statistical reporting and analysis, is a violation of the assurance. All direct identifiers, as well as characteristics that might easily lead to identifying individuals, are omitted from the NPCR and SEER Incidence—U.S. Cancer Statistics Public Use Research Databases. Certain demographic information has been included for research purposes; thus, all SEER\*Stat results must be presented or published in a manner that ensures that no individual can be identified. In addition, there must be no attempt to identify individuals from any computer file or to link with a computer file containing patient identifiers.

Data users must agree to the following provisions before receiving access to the NPCR and SEER Incidence—U.S. Cancer Statistics 2001–2020 and 2005–2020 Public Use Research Databases. ***Please initial after each statement to indicate agreement.***

**As the recipient of access to NPCR and SEER Incidence—U.S. Cancer Statistics Public Use Research Databases:**

- I will adhere to the requirements of the Data Use Agreement and understand that my access to the data will be revoked if these requirements are violated. **Initials:** \_\_\_\_\_
- I understand that all NPCR data are owned by the states and territories. The states and territories have established agreements with CDC regarding the use and dissemination of the data. **Initials:** \_\_\_\_\_
- I will not use or permit others to use the analytic results in any way other than for statistical reporting and analysis. **Initials:** \_\_\_\_\_
- I will use appropriate safeguards to prevent use or disclosure of the information other than as provided for by this agreement. **Initials:** \_\_\_\_\_
- I will ensure all members of the research team who have access to the NPCR and SEER Incidence—U.S. Cancer Statistics Public Use Research Databases through SEER\*Stat have signed this agreement. **Initials:** \_\_\_\_\_
- I will not attempt to link or permit others to link the NPCR and SEER Incidence—U.S. Cancer Statistics Public Use Research Databases with individually identifiable records from any other dataset without CDC's written approval. **Initials:** \_\_\_\_\_
- I will not attempt to use the analytic results or permit others to use them to learn the identity of any person or establishment included in any dataset. **Initials:** \_\_\_\_\_
- I will take the following actions if the identity of any person or establishment is discovered inadvertently:
  - Make no use of this knowledge.
  - Notify CDC by sending an e-mail to [uscdata@cdc.gov](mailto:uscdata@cdc.gov).
  - As requested by CDC, safeguard or destroy the information that identifies an individual or establishment.
  - Inform no one else of the discovered identity. **Initials:** \_\_\_\_\_
- I will make every effort to release all statistical information in such a way as to avoid inadvertent disclosure by:
  - Ensuring that no data on an identifiable case can be derived through subtraction or other calculation from the combination of tables in the given publication. **Initials:** \_\_\_\_\_
  - Ensuring that no data permit disclosure when used in combination with other known data. **Initials:** \_\_\_\_\_

- Not disclosing or otherwise making public data on any unit smaller than 16. If the total number of cases in a cell is fewer than 16, the cell data will be suppressed in oral and written presentations. **Initials:** \_\_\_\_\_
- I have read the data documentation file and understand the data available in the database and the restrictions related to their use. If I have questions regarding my analytic approach, I will contact CDC at [uscdata@cdc.gov](mailto:uscdata@cdc.gov) for assistance. **Initials:** \_\_\_\_\_
- I am familiar with SEER\*Stat in analyzing data or will complete the needed training. **Initials:** \_\_\_\_\_
- I understand that I am responsible for the results of my own analysis. The findings and conclusions resulting from the analysis of these data are those of the authors and do not necessarily represent the official position of CDC. **Initials:** \_\_\_\_\_
- I will acknowledge central cancer registries whenever data are presented, released, or published by including the following (or similar) statement:

These data were provided by central cancer registries participating in CDC's National Program of Cancer Registries (NPCR) and/or NCI's Surveillance, Epidemiology, and End Results (SEER) Program and submitted to CDC and NCI in 2022. **Initials:** \_\_\_\_\_

- As appropriate, I will cite the data in the following way—

*For the 2001–2020 database:* National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program SEER\*Stat Database: NPCR and SEER Incidence—U.S. Cancer Statistics Public Use Research Database, 2022 submission (2001–2020). United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2023. Available at [www.cdc.gov/cancer/public-use](http://www.cdc.gov/cancer/public-use).

*For the 2005–2020 database:* National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER\*Stat Database: NPCR and SEER Incidence—U.S. Cancer Statistics Public Use Research Database with Puerto Rico, 2022 submission (2005–2020). United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2023. Available at [www.cdc.gov/cancer/public-use](http://www.cdc.gov/cancer/public-use).

**Initials:** \_\_\_\_\_

***Users cannot be given access to the U.S. Cancer Statistics databases until SEER Research Plus access is set-up. See the instructions on [page 1](#).***

***When you have access to SEER Research Plus, complete the fields below, sign and date the agreement, and e-mail both pages to [uscdata@imsweb.com](mailto:uscdata@imsweb.com).***

***The e-mail address you provide must be the same one used to obtain access to SEER Research Plus.***

\_\_\_\_\_

**Signature** **Date**

Name: \_\_\_\_\_

Title and organization: \_\_\_\_\_

Telephone number: \_\_\_\_\_ E-mail address: \_\_\_\_\_